MedTrace Logo

Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer

NCT03272217 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-01-07

Study results available
· View outcomes & findings →

Summary

This is a phase II study assessing the activity of bevacizumab combined with atezolizumab in metastatic urothelial carcinoma patients who are ineligible for cisplatin-based therapy.

Conditions

Interventions

DRUG

Atezolizumab

Atezolizumab 1200 mg (flat dose) IV every 21 days

DRUG

Bevacizumab

Bevacizumab 15 mg/kg IV every 21 days

Sponsors & Collaborators

  • Roche-Genentech

    collaborator INDUSTRY

  • Hoosier Cancer Research Network

    collaborator OTHER

  • Arjun Balar, MD

    lead OTHER

Principal Investigators

  • Arjun Balar, M.D. · Hoosier Cancer Research Network

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-13
Primary Completion
2021-05-27
Completion
2022-03-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03272217 on ClinicalTrials.gov